Neumega data

GENIZ (Cambridge, Mass.) announced Phase II results with recombinant human interleukin-11, demonstrating a dose-dependent rise in platelet counts.

Of the 82 patients enrolled, 30 percent of those who received 50 µg/kg daily dose of the cytokine required no platelet transfusions, the primary end point of the study. Only four percent of those given placebo avoided the transfusions. ...